Application of small molecule compound in preparation of medicine for inducing immunogenic cell death

Abstract

The invention relates to the technical field of biological medicine, in particular to application of a small molecule compound in preparation of a medicine for inducing immunogenic cell death. According to the application of the provided small molecule compound in preparation of the medicine for inducing immunogen cell death, the small molecule compound comprises piceatannol, and the piceatannol activates cell autophagy by regulating TFEB / TFE3 so as to synergistically promote oxaliplatin-induced immunogen cell death to generate systemic anti-tumor T cell reaction, so that the immunogen cell death is inhibited, and the immunogen cell death is inhibited. Therefore, in order to enhance the anti-tumor treatment effect, the combined treatment is achieved, the long-lasting anti-cancer immune response can be induced to reduce the possibility of relapse, and the TFEB / TFE3 compound is suitable for being widely applied to activating the potential treatment effect of TFEB / TFE3 in various diseases.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to the application of a small molecular compound in the preparation of drugs for inducing immunogenic cell death. Background technique [0002] While inducing tumor cell death, some chemotherapeutic drugs can induce tumor cell immunogens, causing the surface of tumor cells to express some immunogenic molecules, thereby activating the body's anti-tumor immune response and inducing cytotoxic T cells (CTL, cytotoxic T lymphocytes). ) to kill tumor cells more effectively, so as to achieve a durable and ideal anti-tumor effect. This process is defined as immunogenic cell death (ICD). Recent studies have found that a variety of chemotherapy drugs such as anthracyclines, oxaliplatin, mitoxantrone (MTX), photodynamic therapy, radiotherapy and other drugs and methods for treating tumors can not only cause Tumor cell apoptosis, and can induce ICD. These clinically applied ICD inducers a...

AI Technical Summary

Problems solved by technology

[0006] This application aims to solve the technical problems that some chemotherapeutic drugs such as oxaliplatin (OXA) induce weak immune response when treating cancer in the prior art, resulting in insignificant anti-cancer effect and poor therapeutic effect, and provides a Application of Small Molecular Compounds in the Preparation of Drugs Inducing Immunogenic Cell Death

Images